Exciting News for Kidney Cancer Patients!

Trial results support Ipilimumab plus Nivolumab as a new first line treatment for RCC

Read More Here
Photo Credit: Dr. Bernard Escudier presents Checkmate 214 data in Madrid

Patient Voices

Research

Donate

Latest Post

New first line standard of care treatment for Stage 4 RCC

New data from the pivotal phase 3 Checkmate 214 trial combining ipilumimab and nivolumab presented at the European Society of Medical Oncology (ESMO) conference...Read More

Recent Posts

KCCure Awards Inaugural Grant of $100,000 to Dana Farber for work in CAR T-Cell Research

WASHINGTON – The Kidney Cancer Research Alliance (KCCure) announced today that their first research grant of $100,000 has been awarded to Dr. Wayne Marasco, at ...Read More

Show your colors for World Kidney Cancer Day by helping us fund more research!

Are we green or orange?? That’s a question we get quite often when it comes to kidney cancer.  The answer is YES. And we are black and white.  We are democrats ...Read More

Tweets

Lost Password

Register

Subscribe for updates!